பார்மா அணி News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Tiziana seeks partner in Asia to enhance hepatocellular carcinoma treatment Tiziana seeks partner in Asia to enhance hepatocellular carcinoma treatment 05 May 2021 | News Source credit: Shutterstock Tiziana Life Sciences plc, a UK based biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, announces that it has executed an agreement with Takanawa Japan KK, Pharma Team, for a strategic business development plan to identify a clinical partner in Japan and other Asian countries for further clinical development of Milciclib for treatment in advanced hepatocellular carcinoma (HCC) patients. Previously, Tiziana successfully completed a Phase 2 clinical trial with orally administered Milciclib in sorafenib-resistant or intolerant HCC patients. The clinical data, presented at the American Society of Clinical Oncology (ASCO), demonstrated that the treatment was well-tolerated and produced clinical activity. Recently, a patent co

United statesUnited kingdomTiziana life sciencesAmerican society of clinical oncologyPharma teamTakanawa japanAmerican societyClinical oncologyஒன்றுபட்டது மாநிலங்களில்ஒன்றுபட்டது கிஂக்டம்அமெரிக்கன் சமூகம் ஆஃப் மருத்துவ புற்றுநோயியல்பார்மா அணிஅமெரிக்கன் சமூகம்மருத்துவ புற்றுநோயியல்